Equities

Interpace Biosciences Inc

Interpace Biosciences Inc

Actions
Health CareHealth Care Providers
  • Price (USD)2.66
  • Today's Change-0.02 / -0.75%
  • Shares traded8.21k
  • 1 Year change+153.33%
  • Beta0.6905
Data delayed at least 15 minutes, as of Nov 22 2024 20:52 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments3.504.833.06
Total Receivables, Net4.985.036.16
Total Inventory1.231.221.79
Prepaid expenses0.590.390.80
Other current assets, total0.020.680.36
Total current assets101212
Property, plant & equipment, net2.652.9210
Goodwill, net----8.43
Intangibles, net00.867.29
Long term investments------
Note receivable - long term------
Other long term assets0.050.050.16
Total assets131638
LIABILITIES
Accounts payable1.541.052.69
Accrued expenses9.428.4811
Notes payable/short-term debt02.500
Current portion long-term debt/capital leases5.10--0.08
Other current liabilities, total1.412.252.10
Total current liabilities171416
Total long term debt4.24119.50
Total debt9.34149.58
Deferred income tax------
Minority interest------
Other liabilities, total6.447.079.13
Total liabilities283334
SHAREHOLDERS EQUITY
Common stock0.410.410.40
Additional paid-in capital188188186
Retained earnings (accumulated deficit)(248)(249)(227)
Treasury stock - common(2.01)(1.98)(1.87)
Unrealized gain (loss)------
Other equity, total------
Total equity(15)(17)4.12
Total liabilities & shareholders' equity131638
Total common shares outstanding4.354.304.20
Treasury shares - common primary issue0.100.070.03
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.